Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of bortezomib and low-dose dexamethasone with or without oral cyclophosphamide in relapsed or refractory multiple myeloma
2008-003213-27Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Bortezomib + dexamethasone with Bortezomib + dexamethasone + cyclophosphamide (2 arms). Primary endpoint: Time to progression. Started Aug 2008; status: completed.
02
Drugs
bortezomibdexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-003213-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003213-27.